

Corrigendum

**Corrigendum to “Novel and orally bioavailable inducible
nitric oxide synthase inhibitors: synthesis and evaluation of
optically active 4,5-dialkyl-2-iminoselenazolidine derivatives”**
[Bioorg. Med. Chem. Lett. 15 (2005) 1361]

Shigeo Ueda,^{a,*} Hideo Terauchi,^{a,b} Kenji Suzuki,^a Akihiro Yano,^c Masashi Matsumoto,^c
Taeko Kubo,^c Hisao Minato,^c Yukiyo Arai,^d Jun-ichi Tsuji^c and Nobuhide Watanabe^a

^aChemistry Research Laboratories, Dainippon Pharmaceutical Co. Ltd, Enoki-cho 33-94 Suita, Osaka 564-0053, Japan

^bPharmaceutical Research and Technology Center, Dainippon Pharmaceutical Co., Ltd, Ebie 1-5-51, Fukushima,
Osaka 553-0001, Japan

^cPharmacology and Microbiology Research Laboratories, Dainippon Pharmaceutical Co., Ltd, Enoki-cho 33-94 Suita,
Osaka 564-0053, Japan

^dPharmacokinetics and Physico-Chemical Property Research Laboratories, Dainippon Pharmaceutical Co., Ltd,
Enoki-cho 33-94 Suita, Osaka 564-0053, Japan

Available online 19 March 2005

The publisher would like to point out that there is an error in the fourth sentence of the first paragraph of the fourth page where, ‘When compound **4** was given orally to normal mice at 30 mg/kg/day for 2 weeks, no toxicity in, for instance, hematological test was observed’, should read, ‘When compound **4** was given intravenously to normal mice at 10 mg/kg/day for 2 weeks, no toxicity in, for instance, hematological tests was observed’.